Recruitment of Second Patient for HG-CT-1 Clinical Trial LONDON, GB / ACCESS Newswire / March 17, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce the recruitment of the second p ...
Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapyMONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA, a ...
The tumult of large-scale cuts to federal spending, pullbacks of civil rights protections, and new tariffs getting announced ...
Further information on the abstracts that Roche will present at MDA 2025 can be found below.
Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...
Inter-atrial shunt device therapy has shown mixed results in clinical trials, with clinical 'non-responders' typically showing features of more advanced heart failure. We aimed to analyse the ...
Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...
Established in 2019, Sonder Research X is a Weill Cornell Medical School spin-off company focused on using advanced imaging ...
Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...
Setting boundaries is healthy, but are you using them to control others? Learn how to spot toxic boundary-setting and build ...
Chinese scientists have developed a new treatment for nasopharyngeal carcinoma that helps patients live longer and have a ...
Dr Upul Wijayawardhana That it invariably leads to disaster when politicians attempt to tinker with what they know very little about is well illustrated by what is happening to the British National ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback